Previous 10 | Next 10 |
Greenwich LifeSciences (GLSI +24.4%) is enjoying substantial gains Thursday, continuing a winning streak that began on Tuesday. From the close of trading Monday through Wednesday's close, shares rose ~11%. Year to date through Wednesday's close, shares are down 16%. The recent ...
Gainers: Dermata (NASDAQ:DRMA) +25%. IronNet (NYSE:IRNT) +25%. China Online Education (NYSE:COE) +25%. Greenwich LifeSciences (NASDAQ:GLSI) +25%. CleanSpark (NASDAQ:CLSK) +24%. Ebang International Holdings (NASDAQ:EBON) +22%. Lufax Holding (NYSE:LU) +22%. Vaccinex (NASDAQ:VCNX) +21%. The Vale...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Sne...
Greenwich LifeSciences (NASDAQ:GLSI) provides an update on the Phase III clinical trial, FLAMINGO-01. The combination of GP2 + GM-CSF will be called GLSI-100. The Phase III trial is comprised of 2 placebo-controlled arms for approx. 500 HLA-A*02 patients and 1 open label arm of up to 100 pati...
- The GP2 Phase III clinical trial poster was presented in person at the 2021 annual San Antonio Breast Cancer Symposium (SABCS). The Company was a SABCS sponsor and held a clinical trial planning meeting with investigators at the conference. The poster can be seen here . - Crit...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Markets Go Up, Sentiment...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that CEO...
Greenwich LifeSciences (NASDAQ:GLSI) announces the publication of the GP2 Phase IIb clinical trial at the San Antonio Breast Cancer Symposium 2021 (SABCS). The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did no...
Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence A positive baseline immune response to GP2 in 22.8% of 145 patients suggests an existing immune response to GP2 a...
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
Greenwich LifeSciences Inc. Website:
2024-07-11 21:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, tod...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer r...